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Abstract
Background: Chemoradiotherapy is the standard of care for patients with oesophageal cancer unsuitable for
surgery due to the presence of co-morbidity or extent of disease, and is a standard treatment option for patients
with squamous cell carcinoma of the oesophagus. Modern regimens of chemoradiotherapy can lead to significant
long-term survival. However the majority of patients will die of their disease, most commonly with local
progression/recurrence of their tumours. Cetuximab may overcome one of the principal mechanisms of tumour
radio-resistance, namely tumour repopulation, in patients treated with chemoradiotherapy.
The purpose of this research is first to determine whether the addition of cetuximab to definitive
chemoradiotherapy for treatment of patients with non-metastatic carcinoma of the oesophagus is active (in terms
of failure-free rate), safe, and feasible within the context of a multi-centre randomised controlled trial in the UK. If
the first stage is successful then the trial will continue to accrue sufficient patients to establish whether the
addition of cetuximab to the standard treatment improves overall survival.
Methods/Design: SCOPE1 is a two arm, open, randomised multicentre Phase II/III trial. Eligible patients will have
histologically confirmed carcinoma of the oesophagus and have been chosen to receive definitive
chemoradiotherapy by an accredited multidisciplinary team including a specialist Upper GI surgeon. 420 patients
will be randomised to receive definitive chemoradiotherapy with or without cetuximab using a 1:1 allocation ratio.
During Phase II of the study, the trial will assess safety (toxicity), activity (failure-free rate) and feasibility (recruitment
rate and protocol dose modifications/delays) in 90 patients in the experimental arm. If the experimental arm is
found to be active, safe, and feasible by the Independent Data Monitoring Committee then recruitment will
continue into Phase III. This second stage will recruit a further 120 patients into each arm and compare the overall
survival of both groups.
All patients randomised into Phase II will contribute to the Phase III comparison of overall survival. In addition to
overall survival, Phase III of the study will also assess toxicity, health related quality of life and cost effectiveness.
A detailed radiotherapy protocol and quality assurance procedure has been incorporated into this trial.
Trial registration: ISRCTN: ISRCTN47718479
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Worldwide, oesophageal cancer is the eighth most com-
mon cancer, responsible for an estimated 482,300 new
cases and 406,800 deaths in 2008 and is the fifth highest
in mortality rate among tumour sites [1]. In the UK,
there were 7,966 new cases of oesophageal cancer diag-
nosed in 2007 and it is responsible for approximately 4%
of all cancer deaths with over 7,600 people dying in
2008 [2]. There are two main histological types of oeso-
phageal cancer, squamous cell carcinoma (SCC) and ade-
nocarcinoma (AC). Recently there has been an increase
in the numbers of adenocarcinomas of the lower oeso-
phagus and gastro-oesophageal junction in populations
of the western world [1] whilst the incidence of squa-
mous carcinoma has fallen slightly. In the UK, there has
been a 60% increase in oesophageal carcinoma incidence
in males over the past 30 years [2].
Surgery has long been, and remains, the cornerstone for
cure of oesophageal cancer and is considered for all
patients with potentially resectable oesophageal cancer
who are fit for surgery and have no evidence of distant dis-
ease. Approximately 23% of patients survive 5 years with
the most commonly used surgical treatment strategy [3].
However, rates of surgical intervention in the UK are as
low as 20% of all cases[4]. The most recent figures (for
patients diagnosed between 2001 and 2006) show that the
5-year survival of all patients with oesophageal cancer is
10 per cent [4].
Chemoradiotherapy (CRT) in oesophageal cancer
In a pivotal study [5], US Intergroup RTOG-8501 rando-
mised 121 patients with squamous cell carcinoma (SCC)
or adenocarcinoma (AC) to receive CRT (4 cycles cisplatin
and 5-Fluorouracil (5FU), the first 2 cycles given concur-
rently with 50Gy radiotherapy in 25 fractions) or radio-
therapy alone (64Gy in 32 fractions). This trial, together
with a subsequent systematic review [6], demonstrated a
survival superiority of CRT over radiotherapy alone (1-
year mortality odds ratio 0.61, 95% CI 0.31-0.89, P <
0.001), albeit at the expense of increased toxicity. This and
other reported studies [5,7-12] have been predominantly
in patients with SCC and have demonstrated a remarkably
consistent median survival of 14-18 months and 2 year
overall survival of 30-40% with CRT.
In the UK, most experience has been gained in those
patients, both with SCC and AC, deemed unsuitable for
surgery due to the presence of co-morbidity or extent of
disease [8,13]. Despite the expected poor prognosis of
this patient group, of the 266 patients who were deemed
inoperable at one UK centre between 1995 and 2009, the
median survival was 20.6 months (2 and 5 year survival
44% (95% CI: 37, 50%) and 20% (95% CI: 14, 26%) respec-
tively) [8]. In this study 42% of patients suffered grade 3
and 7% grade 4 toxicities, mainly mucosal and haemato-
logical due to the chemotherapy.
Rational for standard chemotherapy agents
Concurrent CRT regimens have been based upon cisplatin
and 5FU. Both have good single agent activity in oesopha-
geal malignant disease and are amongst the best radio-sen-
sitisers in tumour models [14,15]. The regimen used most
frequently in the UK involves conformal external beam
radiotherapy, 50Gy in 25 fractions over 5 weeks, with 2
cycles cisplatin and 5FU given concurrently, with or with-
out a further 2 cycles of the same chemotherapy, given as
a neo-adjuvant phase [16]. The latter, as well as delivering
additional systemic therapy, allows time for careful radio-
therapy planning, frequently improves the patients’ dys-
phagia and ‘debulks’ the tumour prior to radiotherapy.
5FU has historically been given as a continuous infu-
sion throughout treatment. Capecitabine (Xeloda™), an
oral fluoropyrimidine, sequentially converted to 5FU via
3 enzymes located in liver and tumour tissue, mimics the
effect of continuous infusional 5FU. Capecitabine has
been shown to be at least as effective as infusional 5FU in
advanced oesophago-gastric cancer [17] and the use of
capecitabine instead of infusional 5FU during Upper GI
concurrent CRT has now become standard practice in
some centres e.g. Velindre Cancer Centre, Cardiff and
the Royal Marsden Hospital, Sutton. Capecitabine is also
being used concurrently with radiotherapy to treat other
U p p e rG It u m o u rs i t e s[ 1 8 ] .I n patients with significant
dysphagia capecitabine can be dissolved in warm water
and swallowed or even administered via a naso-gastric
tube.
Cetuximab and anti-EGFR therapies
The majority of patients who relapse do so within the pre-
viously irradiated area [5,10,19]. The reported local failure
rate in recent studies is 45-58% of patients treated with
CRT. This may reflect the advanced nature of the disease,
however factors such as tumour cell repopulation during
radiation therapy have long been known to be an impor-
tant mechanism of radio-resistance [20,21]. Radiotherapy
stimulates tumour cell growth through activation of the
EGF receptor complex causing homodimerisation of the
extracellular receptor inducing autophosphorylation of the
intracellular tyrosine kinase (TK) domain [22], in turn sti-
mulating a number of intracellular signal transduction
pathways such as the ras-raf-MAPK pathway [21]. This
activation sequence can be blocked by the monoclonal
antibody, cetuximab, preventing radiotherapy induced
growth stimulation.
Bonner et al [23] reported results of a trial in patients
with locally advanced squamous cell carcinoma of
the head and neck, a disease with many similarities to
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addition of cetuximab to radiotherapy. 424 patients were
randomised to receive 70-76.8Gy of radiotherapy with or
without cetuximab. Patients were followed up for a
minimum of 2 years. The addition of the antibody was
well tolerated, notably without an increase in mucositis,
although 34% developed predictable and mostly manage-
able G3-4 acute skin reactions (compared to 18%). With
the addition of cetuximab there was improved local con-
trol (47% vs 34% at 3 year, P < 0.01) and overall survival
(55% vs 45% at 3 years, p = 0.05) with nearly a doubling
in median survival (49 vs 29 months). More recently, a
phase II study combining adjuvant cetuximab and CRT
after surgery in patients with head and neck cancer has
shown the addition of cetuximab to be feasible and tol-
erated with predictable toxicity [24].
In patients with metastatic colorectal cancer, cetuximab
has shown significant activity in combination with che-
motherapy in patients who have relapsed on the same che-
motherapy regimen given alone [25]. EXPERT-C, a
randomised phase II study comparing neoadjuvant che-
motherapy before CRT and TME with and without cetuxi-
mab in patients with MRI selected high-risk operable
rectal adenocarcinoma, has shown significant improve-
ment in 3 year OS with the addition of cetuximab (81% vs
96%; HR 0.27, p = 0.035) in the KRAS + BRAF wild type
population although in the all treated population there
was no difference [26]. Skin toxicity was increased with
cetuximab during neoadjuvant chemotherapy and CRT
and diarrhoea was increased during CRT. XERXES, a mul-
ticentre pilot trial to examine the role of cetuximab when
added to a schedule of capecitabine plus pelvic radiation
in patients who have locally advanced primary rectal can-
cers, is still recruiting.
Anti-EGFR therapies have been combined with CRT in
the treatment of thoracic malignancies. 15 patients with
stage III non-small cell lung cancer received gefitinib with
60Gy radiotherapy, given concurrently with carboplatin
and escalating doses of paclitaxel. This anti-EGFR small
molecular agent was well tolerated even in the cohort
receiving full dose chemotherapy, with an impressive
response rate of 91% [27]. RTOG 0324, a Phase II study of
primary CRT and cetuximab in Stage IIIA/B non-small
cell lung cancer, enrolled 93 patients of whom 87 were
evaluable [28]. Response rate was 62%, median survival
was 22.7 months, and 24-month overall survival was
49.3%. Adverse events related to treatment included 20%
grade 4 hematologic toxicities, 8% grade 3 esophagitis, and
7% grade 3 to 4 pneumonitis. It concluded that the combi-
nation of cetuximab with CRT is feasible and shows pro-
mising activity.
In oesophageal cancer, cetuximab has been tested in
combination with irinotecan, cisplatin and concurrent
radiotherapy in Phase II studies: a single centre study
(NCT00165490, 02-012) and in the SWOG-SO414 study.
In the former study, in resectable tumours, 17 of 39
planned patients had completed the protocol by the
ASCO 2006 meeting [29]. Grade 3/4 toxicities seen were
diarrhoea (9 patients), neutropenia (9 patients), febrile
neutropenia (5 patients), anorexia (5 patients), vomiting
(4 patients), fatigue (3 patients) and mucositis (1
patients). The study is still in follow up. The SWOG-
S0414 study, in unresectable tumours, closed due to slow
accrual after recruiting 21 patients. 48% and 29% of
patients had Grade 3 and 4 toxicity respectively [30].
In a larger series, 37 patients with oesophago-gastric can-
cer underwent carboplatin AUC = 2, paclitaxel 50 mg/m2,
cetuximab 250 mg/m2 weekly concurrently with 50.4Gy
radiotherapy. There were no Grade 4 non-haematological
toxicities, 20% of patients had Grade 3 oesophagitis. Eigh-
teen of 27 (67%) had no residual disease on endoscopic
biopsy after treatment and 7 of 16 (43%) who underwent
surgery had a complete pathological response [31]. Build-
ing on their pivotal work with cetuximab and radiotherapy
in head and neck cancer, Dobelbower et al have performed
a Phase 1 study of cisplatin, infusional 5FU, erlotinib (anti-
EGFR small molecule) with 50.4Gy radiotherapy in 11
patients with oesophageal cancer. There were no unex-
pected toxicities [32].
Since the start of the SCOPE1 trial, a phase II study of
neoadjuvant CRT with oxaliplatin and infusional 5-FU
plus cetuximab followed by postoperative docetaxel and
cetuximab has completed in patients with operable adeno-
carcinoma of the oesophagus [33]. It was stopped after 22
patients had been recruited due to unacceptable toxicity (4
post operative deaths all from ARDS) although it showed
promising activity based on pathological complete
response rate (pCR) rate (7 patients). However, a Phase II
study of CRT with FOLFOX plus cetuximab in 79 patients
with locally advanced cardia or oesophageal cancer has
also completed recently and concluded that it is active
(overall response rate after CRT was 77.2%) and has an
acceptable toxicity profile in patients with locally advanced
cardia or oesophageal cancer [34].
Other Phase I/II studies of cetuximab in oesophageal
cancer are still ongoing: EXCEL (NCT00815308, 44
patients in China), FFCD 0505 (NCT00544362, 45 patients
in France), and NCT00425425 (43 patients in Germany).
RTOG 0436, a Phase III trial (420 patients) evaluating the
addition of cetuximab to paclitaxel, cisplatin, and radiation
for patients with oesophageal cancer who are treated with-
out surgery, is still in recruitment. A Swiss Phase III trial
(NCT01107639, 300 patients) giving CRT with or without
cetuximab followed by surgery is also in recruitment.
Endpoint assessment
Assessing response to CRT, without surgically removing
the oesophagus for histological examination, is notoriously
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from 30-80% (mean 61%) [35-42]. Although not a reliable
marker for pCR within the surgically resected speci-
men [38,42] endoscopic response is strongly correlated
with long-term survival [35-37]. No other technique has
been shown to be more reliable though trials are ongoing
into the role of 18-FDG PET and EUS guided FNA in this
setting. PET assesses metabolic activity (as opposed to
size) so is able to determine benign from malignant lesions
and is not only effective in detecting the primary tumour,
but also is more sensitive in detecting small nodal and dis-
tant metastases [43]. It is likely to become more com-
monly used after the results of larger trials and availability
of equipment. It is not clear whether the presence of the
EGF receptor predicts for response to cetuximab.
Although not a pre-requisite for entry into this study, this
and other predictors of response will be the subject of
associated translational research.
Main research question
The main study aim of the SCOPE1 trial is to assess the
effect on overall survival of adding cetuximab to the stan-
dard treatment. We will also examine the effect on toxi-
city, health related quality of life (HRQL), and cost
effectiveness. In this paper we describe the study protocol.
Methods/Design
Study Design
SCOPE1 is a two arm, open, randomised Phase II/III
trial. It is being run in approximately 50 participating
centres throughout the UK. Eligible patients will have
histologically confirmed carcinoma of the oesophagus
(squamous cell, adenocarcinoma, or undifferentiated car-
cinoma) and have been chosen to receive definitive CRT
by an accredited multidisciplinary team (MDT) including
a specialist Upper GI surgeon. At randomisation, partici-
pants are assigned to either the control arm or the
research arm using a 1:1 allocation ratio (see Figure 1).
The control treatment consists of cisplatin (60 mg/m2 IV
Day 1 of 21 day cycle for 4 cycles) and capecitabine (625
mg/m2 po bd Days 1-84) and, from week 7, radiotherapy
(50Gy in 25 fractions over 5 weeks, 2Gy per fraction).
The research arm consists of the above plus cetuximab
(400 mg/m
2 day 1, week 1 only, then 250 mg/m
2 weekly
thereafter for a further 11 weeks).
During Phase II of the study, the trial will assess toxi-
city (unexpected and expected), activity and feasibility in
90 patients in the experimental arm. Activity will be mea-
sured as treatment failure-free rate and feasibility as the
number of protocol dose modifications and delays. If
toxicity, activity and feasibility are found to be unaccepta-
ble recruitment into the trial will stop. If the experimen-
tal arm is found to be active, safe and feasible, by the
Independent Data Monitoring Committee (IDMC),
recruitment will continue into Phase III of the study.
Phase III of the study will recruit a further 120 patients
into each arm (a total of 420 patients) and compare the
overall survival of both groups. The experimental arm of
CRT and cetuximab will be compared against the control
arm of CRT alone. This second stage of the trial is pow-
ered to detect a survival advantage with the addition of
cetuximab.
All patients randomised into Phase II will contribute to
the Phase III comparison of overall survival. In addition
to overall survival, Phase III of the study will also assess
toxicity, HRQL, and cost effectiveness.
Detailed radiotherapy treatment protocols have been
notably absent in recent UK Upper GI Cancer trials
involving CRT, as have procedures to assess adherence to
treatment recommendations. Therefore a detailed radio-
therapy protocol and quality assurance procedure (Radio-
therapy Trials Quality Assurance (RTTQA)) will be
incorporated into this trial.
SCOPE1 has been ethically approved by the Research
Ethics Committee for Wales and has approval from the
Medicines and Health Care Product Regulatory Agency
to be conducted in the UK. The Wales Cancer Trials
Unit, a Cancer Research UK core funded and National
Cancer Research Institute accredited Clinical Trials Unit,
is coordinating the trial. Velindre NHS Trust is the spon-
sor for the trial. A Trial Steering Committee and an Inde-
pendent Data Monitoring Committee has been set up to
monitor the progress and safety of the study. The
SCOPE1 Trial Management Group, including clinicians,
clinical trial unit staff, patient representatives, nursing
and pharmacy representatives, carry out the day-to-day
running of the trial.
Participant Eligibility
Eligible patients will have been diagnosed with carcinoma
of the oesophagus, AC, SCC, or undifferentiated carci-
noma, or Siewert Type 1 or 2 tumour of the gastro-oeso-
phageal junction (GOJ) and selected for treatment with
definitive CRT by an appropriate specialised MDT. Such
patients may enter the trial if they meet all the necessary
inclusion and none of the exclusion entry criteria (see
Table 1).
Within 8 weeks prior to randomisation, a spiral/multi-
slice CT scan (+/- PET) and an endoscopic ultrasound
(to include recording of proximal and distal extent of pri-
mary tumour, location of lymphadenopathy and refer-
ence point for localisation on CT planning) should be
performed. One of these assessments should be carried
out within 4 weeks. Within 1 week prior to randomisa-
tion the following screening assessments should be per-
formed: a history and physical examination (to include
height, weight and WHO performance status); full blood
count; serum renal, liver and bone profile (including
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diogram; and pregnancy test in females of child bearing
age.
Sample Size Considerations
Phase II
The treatment failure-free rate in patients treated with
CRT is approximately 60% at 24 weeks [35,42]. With the
addition of cetuximab it is felt that a treatment failure-
free rate of less than 60% would not be sufficiently large
enough to warrant further investigation in a Phase III set-
ting, but that a rate of 75% or higher would warrant
further investigation. Using a Fleming’ss i n g l es t a g e
design, p1 = 0.60 and p2 = 0.75, setting a = 0.05 and 90%
power 83 patients would be required. To allow for 10%
not being assessable and with a 1:1 allocation 90 patients
will be recruited into each arm, a total of 180 patients.
The IDMC will review the treatment failure-free rate,
along with toxicity and feasibility, before they endorse
continuation into Stage 2.
Phase III
Calculations were performed using the ART package [44]
in Stata 9 assuming a 3 year recruitment period followed
by 1 year of follow up (based on a 2-sided log rank test).
The 2 year overall survival rate in patients treated with
CRT is approximately 35%. In order to detect an improve-
ment in 2 year overall survival from 35% to 47.5% (Hazard
Ratio [HR] = 0.71) with 80% power at a 5% significance
level a total of 420 patients (269 events) are required. A
total of 210 patients will be recruited to each arm.
Method of Randomisation
Patients are randomised centrally by the Wales Cancer
Trials Unit using the method of minimisation which
includes a random element. Patients are stratified for a
number of clinically important stratification factors. The
Figure 1 Trial Schema.
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will be 1:1.
Outcome Measures
Phase II
The primary outcome measure is treatment failure rate
in the research arm. Treatment failure rate will be
assessed at 24 weeks (12 weeks after completion of
CRT) and is defined as pathologically confirmed (by
endoscopic assessment and/or biopsy) residual disease
and/or CT scan of thorax and abdomen showing pro-
gressive disease according to RECIST criteria. Treatment
failure will also include progression or death due to dis-
ease before 24 weeks.
Table 1 Inclusion and exclusion criteria for the SCOPE1 trial
Inclusion Criteria
Patients meeting the following criteria can be included in the trial:
1. Histologically confirmed carcinoma of the oesophagus (adenocarcinoma or squamous cell or undifferentiated carcinoma) or Siewert Type 1
tumour of the gastro-oesophageal junction (GOJ) or Siewert Type 2 with no more than 2 cm mucosal extension into the stomach.
2. Age 18 or over
3. Have been selected to receive potentially curative definitive CRT by a specialist Upper GI MDT including a designated Upper GI surgeon.
4. Not suitable for surgery either for medical reasons or through patient choice.
5. Tumours staged with both endoscopic ultrasound (EUS) and spiral CT scan to be T1-4, N0-1 confirming localised, non-metastatic disease (both
within 7 weeks prior to randomisation, but the most recent within 4 weeks). An attempted but failed or contra-indicated EUS is acceptable. Tumours
should be staged according to the 6th edition of the American Joint Committee on Cancer’s (AJCC) Cancer Staging Manual
6. Total disease length (primary and lymph nodes) less than or equal to 10 cm defined by EUS or CT if EUS attempted but failed or contra-indicated.
7. WHO Performance status 0-1
8. Adequate cardiovascular function for safe delivery of CRT in the opinion of the principal investigator
9. Adequate respiratory function for safe delivery of CRT in the opinion of the Principal Investigator
10. Adequate bone marrow and hepatic function (within 1 week prior to randomisation):
￿ Absolute neutrophil count (ANC) ≥ 1.5 × 10
9/L
￿ White blood cell count ≥ 3×1 0
9/L
￿ Platelets ≥ 100 × 10
9/L
￿ Haemoglobin (Hb) ≥ 10 g/dL (patients’ Hb should be corrected to > 10 g/dl before treatment)
￿ Adequate liver function (within 1 week prior to randomisation)
￿ Serum bilirubin ≤ 1.5× ULN
￿ ALT/AST ≤ 2.5× ULN
￿ ALP ≤ 3× ULN
11. Adequate renal function (within 1 week prior to randomisation): Glomerular filtration rate (GFR) assessed by EDTA clearance to be > 40 mL/min
(or estimated by Cockcroft-Gault formula to be > 60 mL/min)
12. Patients who are fit to receive all protocol treatment.
13. Patients who are able and willing to administer capecitabine.
14. Patients who are of child bearing age are willing to use contraception.
15. Patients who have completed baseline quality of life questionnaires
16. Patients who have provided written informed consent prior to randomisation
Exclusion Criteria
If any of the following criteria apply, patients cannot be included in the trial:
1. Patients who have had previous treatment for invasive oesophageal carcinoma or gastro-oesophageal junction carcinoma (not including PDT or
laser therapy for high grade dysplasia/carcinoma in-situ).
2. Patients with metastatic disease i.e. M1a or M1b according to UICC TNM version 6.
3. Patients with any previous treatment for malignancy which will compromise ability to deliver definitive mediastinal CRT or may compromise
survival (does not include patients with squamous cell carcinoma).
4. Patients who have had a previous malignancy during the previous 5 years
5. Patients with significant (> 2 cm) extension of tumour into the stomach
6. Patients with unstable angina or uncontrolled hypertension or cardiac failure or other clinically significant cardiac disease
7. Patients who have had major surgery or major trauma in the 4 weeks prior to randomisation.
8. Patients who have been treated with a monoclonal antibody in the 4 weeks prior to randomisation.
9. Patients who have been treated with radiotherapy in the 3 months prior to randomisation
10. Patients who need continued treatment with a contraindicated concomitant medication or therapy
11. Patients with known dihydropyrimidine dehydrogenase (DPD) deficiency
12. Patients with hearing impairment or sensory-motor neuropathy of WHO grade > 2
13. Women who are pregnant
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￿ Toxicity: will be scored using the NCI CTCAE
v3.0 and RTOG late radiation morbidity scoring cri-
teria at baseline, during treatment and at pre-speci-
fied time points on follow-up. Serious adverse events
will be monitored “real-time” by the Chief Investiga-
tor and TMG.
￿ Feasibility: will be measured through the number
of protocol dose modifications and delays.
Phase III
The primary outcome measure is overall survival (OS).
Overall survival is calculated from the date of randomi-
sation to death from any cause. Those patients still alive
will be censored at the date last seen.
The secondary outcome measures are: toxicity (as
above), HRQL, RTTQA and cost effectiveness:
￿ HRQL: This aspect of the trial aims determine
whether cetuximab in addition to CRT:
◦ improves generic and disease specific aspects of
HRQL following treatment than CRT alone. Speci-
fic HRQL domains that are expected to be better
in the experimental group are: physical and role
function, fatigue, dysphagia and eating restrictions
◦ is associated with poorer HRQL during treat-
ment. Specific HRQL domains that are expected to
be worse in the experimental arm include: dys-
pnoea, skin rashes and diarrhoea.
Generic domains of HRQL will be assessed with the
EORTC core Quality of Life Questionnaire, the EORTC
QLQ-C30 [45]. This instrument has been well validated in
many international clinical trials in oncology including
oesophageal adenocarcinoma and squamous cell cancer.
Disease specific and CRT associated symptoms and side
effects will be assessed with the oesophageal cancer speci-
fic module, the EORTC QLQ-OES18 [46]. This has been
validated and tested in patients receiving definitive CRT.
The module includes scales assessing dysphagia, eating
restrictions, reflux, dry mouth and problems with saliva
and deglutition. The Dermatology Life Quality Index
(DLQI) will also be administered [47]. This is a well vali-
dated, easy to use index which assesses the impact of der-
matological conditions on patients’ HRQL [48]. It has
been included to accurately assess the impact of the acnei-
form eruption commonly seen with cetuximab. All
patients who participate in the SCOPE1 study will com-
plete questionnaires at: baseline, during and at end of
treatment (Week 7 and week 13), post treatment (24
weeks, time of endoscopy and scan), 12, 18, 24 months
and annually to 60 months.
￿ Cost effectiveness: A cost-utility analysis of cetux-
imab in addition to CRT in oesophageal cancer will
be performed from the perspective of the UK
National Health Service, but with consideration also
given to patient and family related costs. The cost-
effectiveness will be considered using two time hori-
zons: within trial and lifetime. In order to undertake
the latter a decision-analytic model will be developed
to assess the costs and effects over the lifetime of
patients. The model will be a Markov model and the
transition probabilities will be based on parameter
estimates derived from the trial (and other sources
from within the literature). The within trial compo-
nent will involve a comparison of the additional
costs associated with the use of cetuximab in the
treatment regimen ± any changes in resources uti-
lised elsewhere. Costs of cetuximab will be based on
discussions with clinicians and finance staff, while
other healthcare resources utilised by patients during
the study period will be collected via the healthcare
resource utilisation log administered during treat-
ment and at follow-up. At each of the 3-4 weekly
visits, patients will be asked to indicate whether they
have had any contacts with their GP, practice nurse,
community nurse or attended hospital either as an
outpatient or in-patient. They will be asked whether
the contact was connected to their condition or for
any other purpose. The involvement of others in
providing transport and/or support will also be
logged. In addition, they will be asked to indicate the
medication they have been taking during the 3-4
week period. Consultations with healthcare profes-
sionals will be costed using published sources of unit
costs and healthcare resources utilised will be added
to the respective treatment costs in each arm. Qual-
ity adjusted life years (QALYs) will be derived from
survival data generated during the second stage of
the trial and from the EQ-5D scores collected at
baseline, during treatment and at follow-up. A
patient diary will also be used to collect additional
data. These data will then be used to populate the
lifetime model.
￿ RTTQA: A detailed QA program will be in place
to ensure adherence to the protocol (see RTTQA
section below). Major and minor deviations will be
collected.
NB: Although activity, safety and feasibility will not be
formally assessed in the control arm in Phase II, the
randomisation of patients will continue using the same
process and on a 1:1 allocation and therefore those
patients in Phase II will be included in the analysis of
Phase III.
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Participants will be seen at hospital at randomisation, the
end of each treatment cycle, then at Month 6, 9, 12, 16,
20, 24, 36, 48, and 60 after randomisation. Research staff
at the hospitals will be expected to complete trial CRFs
which record evidence of primary and secondary out-
come measures.
Statistical analysis
All analyses will be on an intention-to-treat basis, i.e. all
patients randomised will be included, and all patients will
be analysed according to their allocated group whatever
treatment they received. Both Phase II and Phase III ana-
lyses will include:
￿ Descriptive statistics of the patient characteristics
within each treatment group
￿ A CONSORT flow diagram of enrolment, inter-
vention allocation, and follow-up
￿ Tables of toxicities at each timepoint (baseline, end
of each treatment cycle, then Month 6, 9, 12, 16, 20,
24, 36, 48, 60)
￿ Treatment compliance during each cycle (in terms
of proportions of patients with delay/reduction to
CRT) within each treatment group. An exploration
of predictors of poor compliance will be performed.
Phase II
When 6 month follow up data has been obtained for 83
patients in the research arm then the Stage 1 analysis
will be performed. According to the Flemings design, we
need to see 58 “failure free” patients out of 83 patients
followed up to 6 months in the research arm.
Phase III
The main analysis will compare overall survival between
the two groups using unadjusted logrank test. Final ana-
lysis will take place when 269 events (deaths) have been
reported, which is expected to be approximately 1 year
after accrual closes. The secondary outcome of propor-
tions of patients with SAEs will be compared using a chi-
squared test.
No formal subgroup analyses are planned to look at
differences in primary and secondary endpoints between
treatment groups within specific groupings based on
patient characteristics. However, if any treatment differ-
ence is found we will look to see whether it is consistent
across patient subgroups (defined by all pre-treatment
factors collected) although th i sa n a l y s i sw i l lb ee x p l o r a -
tory in nature.
The HRQL data will be scored according to the algo-
rithms described in the EORTC QLQ-C30 scoring man-
ual [49]. All scales and single items are scored on
categorical scales and linearly transformed to 0-100
scales where: (a) a high score for a symptom scale or
item represents a high level of symptoms or problems,
and (b) a high score for a functional scale represents a
high or health level of functioning and a high score for
the global health status/HRQL represents high QL.
Groups of patients will be compared at agreed time
points and overall for differences in these parameters.
The treatment groups will be compared at the individual
time points with appropriate adjustments being made for
multiple comparisons. Because of the longitudinal nature
of the data, an analysis that takes into account the
repeated measures is also needed. A generalised linear
modelling approach will be adopted. This will allow the
appropriate error distribution to be used and will enable
t h ea n a l y s i st ot a k ea c c o u n to fi m p o r t a n tp r o g n o s t i c
factors.
The economic evaluation will assess the differences in
mean costs between the trial arms and use with the dif-
ferences in QALYs to generate a cost per QALY estimate.
The EQ-5D allows estimation of quality adjusted life
years (QALYs) which will be the main effectiveness mea-
sure in the economic analysis. Between group differences
will be estimated using the area under the curve method
adjusted for differences at baseline. Since cost data are
often skewed, bootstrapping methods will be used to pro-
duce 95% confidence intervals alongside point estimates.
A probabilistic sensitivity analysis will be undertaken and
a cost-effectiveness acceptability curve produced. In addi-
tion, a series of one-way sensitivity analyses will be
undertaken to assess the robustness of the estimate to
changes in costs, resources utilised, utility scores and
QALYs. In the case of non-dominance, results will be
reported in the form of an incremental cost effectiveness
ratio (ICER) which shows the extra cost of producing one
extra QALY. A cost-effectiveness acceptability curve
(CEAC) will be used to calculate 95% confidence inter-
vals for the incremental cost effectiveness ratios.
Radiotherapy Quality Assurance
The RTTQA for SCOPE1 consists of clinical oncologists,
dosimetrists, trial management, medical physicist and
research fellows. It is part of the NCRI RTTQA group.
An educational CD ROM is being distributed to all
investigators. This CD ROM includes three example cases,
each of which consists of a clinical summary, CT slice
data, outlines and Radiotherapy plan information. GUI-
NESS software is provided for viewing the CT, outline and
planning data. A radiotherapy treatment planning and
delivery protocol has been written and is supplied in hard
copy and electronically on the CD ROM.
All clinical and radiation oncologists participating in the
trial are required to outline a test case (CT data set for
which is included on the educational CD ROM). All plan-
ning departments are required to plan this test case. This
would usually be carried out on the outline completed by
the Principal Investigator. A Plan Assessment Form (PAF)
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Page 8 of 11is completed that compares the planned test case with the
delivery protocol for major and minor deviations. This,
together with the completed plan, is assessed centrally by
the SCOPE1 RTTQA team. All centres and Investigators
must have a ‘Pass’ for the planned test case before entering
patients into the trial.
On trial, centres are required to provide a PAF and a full
dataset of images, structures, plan and doses, for each
patient. The first clinical case from each investigator, a
10% sample and those with noted major deviations (on the
PAF) from the protocol will be assessed centrally by the
SCOPE1 RTTQA in real time.
Discussion
This Cancer Research UK funded trial will define the most
effective CRT regimen in terms of overall survival for
patients with oesophageal cancer unsuitable for surgery
due to the presence of co-morbidity or extent of disease.
The Phase II/III design allows an early assessment of activ-
ity and toxicity of cetuximab in this context before pro-
gressing to the definitive Phase III endpoint. This provides
an early stopping opportunity whilst also allowing trial
momentum to be maintained. This efficiency saves years
compared to running concurrent Phase II and Phase III
trials by having one rather than two funding and regula-
tory approval applications and centre set up processes.
This trial builds in health economic and HRQL measures
which provide a well-rounded assessment of the impact of
the experimental regimen. It also has a RTTQA compo-
nent which standardises radiotherapy delivery within the
trial.
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